Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in Serum
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Parkinson's Disease (PD) is the second most common neurodegenerative disorder of the central nervous system. Motor symptoms are the focus of pharmacotherapy, yet non-motor features of the disease (e.g. fatigue, mood disturbances, sleep disturbances and symptoms of anxiety) are both common and disabling for the patient. The pathophysiological mechanisms behind the non-motor symptoms in PD are yet to be untangled. The main objective of this study was to investigate associations between pro-inflammatory substances and non-motor symptoms in patients with PD. METHODS AND MATERIALS: We measured C-reactive protein, interleukin (IL)-6, soluble IL-2 receptor (sIL-2R) and tumor necrosis factor-α (TNF-α) in blood samples from PD patients (n=86) and healthy controls (n=40). Symptoms of fatigue, depression, anxiety and sleeping difficulties were assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT), the Hospital Anxiety and Depression Scale (HAD), and the Scales for Outcome in PD-Sleep Scale respectively. RESULTS: IL-6 was significantly higher in PD patients than in healthy controls. Compared to healthy controls, PD patients displayed significantly higher mean scores on HAD and lower scores on FACIT, thus indicating more severe symptoms as measured with these scales. Within the PD sample, high levels of both sIL-2R and TNF-α were significantly associated with more severe symptoms assessed by means of FACIT and HAD (depression and anxiety subscales). SIL-2-R levels were able to significantly predict FACIT and HAD scores after the effects of age, gender, anti-parkinsonian medications, and severity of motor symptoms were controlled for. DISCUSSION: We suggest that non-motor symptoms in PD patients, such as fatigue and depressive symptoms, might be generated via inflammatory mechanisms. This knowledge might contribute to the development of novel treatment options in PD, specifically targeting non-motor symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increased levels of IL-6 in PD patients’ serum have been reported in a number of studies [254,255,256]”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [254]
In the citing paper
“proinflammatory cytokines could play a role in the nonmotor symptoms of PD [42]”
From Neuroprotective Effect of Ceftriaxone on MPTP‐Induced Parkinson’s Disease Mouse Model by Regulating Inflammation and Intestinal Microbiota (2021) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Interleukin-2: Inception, Impact, and Implications
Smith, K. A. (1988) · Science · doi:10.1126/science.3131876 · Cited by 2,153
Twenty years of research on cytokine-induced sickness behavior
Dantzer, R., & Kelley, K. W. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2006.09.006 · Cited by 1,420
Cytokines and major depression
Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.003 · Cited by 1,235 · cited 5×
“However, there are preliminary clinical trials of MDD patients without PD indicating that NSAIDs as add-on to conventional antidepressants may have beneficial effects on depressive symptoms [42,43].”
InfluentialLiu, Y., Ho, R. C.-M., & Mak, A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.003 · Cited by 948
Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (2013) · PsycTESTS Dataset · doi:10.1037/t03589-000 · Cited by 946
Blum-Degena, D., Müller, T., Kuhn, W., Gerlach, M., Przuntek, H., & Riederer, P. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12192-7 · Cited by 801
Cited by
Inflammation and immune dysfunction in Parkinson disease
Tansey, M. G., Wallings, R. L., Houser, M. C., Herrick, M. K., Keating, C. E., & Joers, V. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00684-6 · Cited by 1,382
Oxidative stress, mitochondrial damage and neurodegenerative diseases.
Guo, C., Sun, L., Chen, X., & Zhang, D. (2013) · PubMed · doi:10.3969/j.issn.1673-5374.2013.21.009 · Cited by 1,298
Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight
Bhat, A. H., Dar, K. B., Anees, S., Zargar, M. A., Masood, A., Sofi, M. A., & Ganie, S. A. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.07.025 · Cited by 928
The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?
Houser, M. C., & Tansey, M. G. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-016-0002-0 · Cited by 588
Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy
Muzio, L., Viotti, A., & Martino, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.742065 · Cited by 581
“Along the same lines, high levels of both soluble IL-2 receptor (IL-2R) and TNF-α in blood samples of PD patients were significantly associated with more severe symptoms of the disease (Lindqvist et al., 2012).”
BackgroundQin, X.-Y., Zhang, S.-P., Cao, C., Loh, Y. P., & Cheng, Y. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2742 · Cited by 554
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
Mitophagy: An Emerging Role in Aging and Age-Associated Diseases
Chen, G., Kroemer, G., & Kepp, O. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00200 · Cited by 359
Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE‐PD)
Williams‐Gray, C. H., Wijeyekoon, R., Yarnall, A. J., Lawson, R. A., Breen, D. P., Evans, J. R., Cummins, G. A., Duncan, G. W., Khoo, T. K., Burn, D. J., et al. (2016) · Movement Disorders · doi:10.1002/mds.26563 · Cited by 304
Cellular Senescence in Neurodegenerative Diseases
Martínez-Cué, C., & Rueda, N. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00016 · Cited by 281
Lindqvist, D., Hall, S., Surova, Y., Nielsen, H. M., Janelidze, S., Brundin, L., & Hansson, O. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.07.007 · Cited by 276
Self-citationThe Contribution of Microglia to Neuroinflammation in Parkinson’s Disease
Badanjak, K., Fixemer, S., Smajić, S., Skupin, A., & Grünewald, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094676 · Cited by 276
Depression in neurodegenerative diseases: Common mechanisms and current treatment options
Galts, C. P. C., Bettio, L. E. B., Jewett, D. C., Yang, C. C., Brocardo, P. S., Rodrigues, A. L. S., Thacker, J. S., & Gil-Mohapel, J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.002 · Cited by 269
Biomarker of Neuroinflammation in Parkinson’s Disease
Liu, T.-W., Chen, C.-M., & Chang, K.-H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084148 · Cited by 259
Dursun, E., Gezen-Ak, D., Hanağası, H., Bilgiç, B., Lohmann, E., Ertan, S., Atasoy, İ. L., Alaylıoğlu, M., Araz, Ö. S., Önal, B., et al. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.04.014 · Cited by 237
Sanchez-Guajardo, V., Barnum, C. J., Tansey, M. G., & Romero-Ramos, M. (2013) · ASN Neuro · doi:10.1042/an20120066 · Cited by 236
Inflammation is genetically implicated in Parkinson’s disease
Dzamko, N., Geczy, C. L., & Halliday, G. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.028 · Cited by 222
Rocha, N. P., de Miranda, A. S., & Teixeira, A. L. (2015) · BioMed Research International · doi:10.1155/2015/628192 · Cited by 199
Effects of COVID‐19 on Parkinson's Disease Clinical Features: A Community‐Based Case‐Control Study
Cilia, R., Bonvegna, S., Straccia, G., Andreasi, N. G., Elia, A. E., Romito, L. M., Devigili, G., Cereda, E., & Eleopra, R. (2020) · Movement Disorders · doi:10.1002/mds.28170 · Cited by 185
Montan, I., Löwe, B., Cella, D., Mehnert, A., & Hinz, A. (2018) · Value in Health · doi:10.1016/j.jval.2018.03.013 · Cited by 183
Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses
Morris, G., Berk, M., Walder, K., & Maes, M. (2015) · BMC Medicine · doi:10.1186/s12916-014-0259-2 · Cited by 181
Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders
Kalkman, H. O., & Feuerbach, D. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2175-4 · Cited by 181
Immune system responses in Parkinson's disease: Early and dynamic
Tansey, M. G., & Romero‐Ramos, M. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14290 · Cited by 178
Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair
Vivekanantham, S., Shah, S., Dewji, R., Dewji, A., Khatri, C., & Ologunde, R. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2014.982795 · Cited by 171
“This is an important finding because if we can manage to find an effective method to decrease inflammation in PD we might be able to treat both the motor and non-motor symptoms [28].”
BackgroundPrange, S., Klinger, H., Laurencin, C., Danaila, T., & Thobois, S. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00942-1 · Cited by 167
Strategies for the Treatment of Parkinson’s Disease: Beyond Dopamine
Iarkov, A., Barreto, G. E., Grizzell, J. A., & Echeverría, V. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00004 · Cited by 164
Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease
Lim, C. K., Fernández-Gomez, F. J., Braidy, N., Estrada, C., Costa, C., Costa, S., Bessede, A., Fernandez-Villalba, E., Zinger, A., Herrero, M. T., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.009 · Cited by 159
Parkinson disease with constipation: clinical features and relevant factors
Yu, Q.-J., Yu, S.-Y., Zuo, L.-J., Lian, T.-H., Hu, Y., Wang, R.-D., Piao, Y.-S., Guo, P., Liu, L., Jin, Z., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-16790-8 · Cited by 134
Ahmad, M. H., Rizvi, M. M. A., Ali, M., & Mondal, A. C. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101840 · Cited by 152
Parkinson's disease‐related fatigue: A case definition and recommendations for clinical research
Kluger, B. M., Herlofson, K., Chou, K. L., Lou, J., Goetz, C. G., Lang, A. E., Weintraub, D. A., & Friedman, J. H. (2016) · Movement Disorders · doi:10.1002/mds.26511 · Cited by 143
Barnum, C. J., Chen, X., Chung, J., Chang, J., Williams, M., Grigoryan, N., Tesi, R. J., & Tansey, M. G. (2014) · Journal of Parkinson's Disease · doi:10.3233/jpd-140410 · Cited by 124
The Link between Gut Dysbiosis and Neuroinflammation in Parkinson’s Disease
Baizabal-Carvallo, J. F., & Alonso-Juarez, M. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.02.030 · Cited by 130
Tanaka, S., Ishii, A., Ohtaki, H., Shioda, S., Yoshida, T., & Numazawa, S. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-143 · Cited by 118
Álvarez-Luquín, D. D., Arce-Sillas, A., Leyva-Hernández, J., Sevilla-Reyes, E., Boll, M. C., Montes-Moratilla, E., Vivas-Almazán, V., Pérez-Correa, C., Rodríguez-Ortiz, U., Espinoza-Cárdenas, R., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1606-1 · Cited by 108
Gut feelings about smoking and coffee in Parkinson's disease
Derkinderen, P., Shannon, K. M., & Brundin, P. (2014) · Movement Disorders · doi:10.1002/mds.25882 · Cited by 115
Peripheral blood inflammatory markers in early Parkinson’s disease
Kim, R., Kim, H.-J., Kim, A., Jang, M., Kim, A., Kim, Y., Yoo, D., Im, J. H., Choi, J.-H., & Jeon, B. (2018) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2018.10.079 · Cited by 103
Hou, L., Sun, F., Huang, R., Sun, W., Zhang, D., & Wang, Q. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101134 · Cited by 108
Mulas, G., Espa, E., Fenu, S., Spiga, S., Cossu, G., Pillai, E., Carboni, E., Simbula, G., Jadzic, D., Angius, F., et al. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.09.013 · Cited by 114
Parkinson disease with REM sleep behavior disorder: Features, α-synuclein, and inflammation
Hu, Y., Yu, S.-Y., Zuo, L.-J., Cao, C.-J., Wang, F., Chen, Z.-J., Du, Y., Lian, T.-H., Wang, Y.-J., Chan, P., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001308 · Cited by 99
Peripheral Immune Profile and Neutrophil‐to‐Lymphocyte Ratio in Parkinson's Disease
Muñoz‐Delgado, L., Macías‐García, D., Jesús, S., Martin‐Rodríguez, J. F., Labrador‐Espinosa, M. Á., Jiménez‐Jaraba, M. V., Adarmes-Gómez, A. D., Carrillo, F., & Mir, P. (2021) · Movement Disorders · doi:10.1002/mds.28685 · Cited by 109
Eidson, L. N., Kannarkat, G. T., Barnum, C. J., Chang, J., Chung, J., Caspell-Garcia, C., Taylor, P., Mollenhauer, B., Schlossmacher, M. G., Ereshefsky, L., et al. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0935-1 · Cited by 102
C-Reactive Protein and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis
Qiu, X., Xiao, Y., Wu, J., Gan, L., Huang, Y., & Wang, J. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00384 · Cited by 101
Pathogenesis of α-Synuclein in Parkinson’s Disease: From a Neuron-Glia Crosstalk Perspective
Yi, S., Wang, L., Wang, H., Ho, M. S.-C., & Zhang, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314753 · Cited by 102
Increased peripheral inflammation in asymptomatic leucine‐rich repeat kinase 2 mutation carriers
Dzamko, N., Rowe, D. B., & Halliday, G. M. (2016) · Movement Disorders · doi:10.1002/mds.26529 · Cited by 98
Adult Hippocampal Neurogenesis in Parkinson’s Disease: Impact on Neuronal Survival and Plasticity
Regensburger, M., Prots, I., & Winner, B. (2014) · Neural Plasticity · doi:10.1155/2014/454696 · Cited by 85
Fatigue in Parkinson's disease
Herlofson, K., & Kluger, B. M. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.12.061 · Cited by 95
COPPADIS Study Group, Santos‐García, D., Mir, P., Cubo, E., Vela, L., Rodríguez-Oroz, M. C., Martí, M. J., Arbelo, J. M., Infante, J., Kulisevsky, J., et al. (2016) · BMC Neurology · doi:10.1186/s12883-016-0548-9 · Cited by 89
Zhou, X., Lu, J., Wei, K., Wei, J., Tian, P., Yue, M., Wang, Y., Hong, D., Li, F., Wang, B., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9424582 · Cited by 85
“There is an increase in proinflammatory microorganisms in the intestinal microbiota of PD patients [41], and proinflammatory cytokines could play a role in the nonmotor symptoms of PD [42].”
Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates
Dugan, L. L., Tian, L., Quick, K. L., Hardt, J. I., Karimi, M., Brown, C., Loftin, S. K., Flores, H., Moerlein, S. M., Polich, J. M., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24220 · Cited by 85
Kouchaki, E., Kakhaki, R. D., Tamtaji, O. R., Dadgostar, E., Behnam, M., Nikoueinejad, H., & Akbari, H. (2018) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2018.01.022 · Cited by 85
Fatigue in Patients with Multiple Sclerosis: Is It Related to Pro- and Anti-Inflammatory Cytokines?
Malekzadeh, A., Van de Geer-Peeters, W., De Groot, V., Elisabeth Teunissen, C., Beckerman, H., & Study Group, T.-A. (2015) · Disease Markers · doi:10.1155/2015/758314 · Cited by 73
Intestinal Inflammation and Parkinson’s Disease
Li, Y., Chen, Y., Jiang, L., Zhang, J., Tong, X., Chen, D., & Le, W. (2021) · Aging and Disease · doi:10.14336/ad.2021.0418 · Cited by 80
Role of neuroinflammation and latent transcription factors in pathogenesis of Parkinson’s disease
Pal, R., Tiwari, P. C., Nath, R., & Pant, K. K. (2016) · Neurological Research · doi:10.1080/01616412.2016.1249997 · Cited by 71
Quansah, E., Peelaerts, W., Langston, J. W., Simon, D. K., Colca, J., & Brundin, P. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0260-x · Cited by 75
Tönges, L., Buhmann, C., Klebe, S., Klucken, J., Kwon, E. H., Müller, T., Pedrosa, D. J., Schröter, N., Riederer, P. F., & Lingor, P. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02498-1 · Cited by 76
Pereira, J. R., dos Santos, L. V., Santos, R. M. S., Campos, A. L. F., Pimenta, A. L., de Oliveira, M. S., Bacheti, G. G., Rocha, N. P., Teixeira, A. L., Christo, P. P., et al. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.09.030 · Cited by 76
Role of exosomes in the pathogenesis of inflammation in Parkinson’s disease
Yang, X., Li, K., Huang, H., & Ren, H. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335143 · Cited by 74
Rathnayake, D., Chang, T., & Udagama, P. V. (2019) · BMC Neurology · doi:10.1186/s12883-019-1286-6 · Cited by 73
Serum inflammatory cytokines levels and the correlation analyses in Parkinson’s disease
Fu, J., Chen, S., Liu, J., Yang, J., Ou, R., Zhang, L., Chen, X., & Shang, H. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1104393 · Cited by 69
Behl, T., Kaur, I., Sehgal, A., Singh, S., Bhatia, S., Al‐Harrasi, A., Zengin, G., Bumbu, A. G., Andronie-Cioară, F. L., Nechifor, A. C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136737 · Cited by 67
Hou, L., Sun, F., Sun, W., Zhang, L., & Wang, Q. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.09.006 · Cited by 67
Xiromerisiou, G., Marogianni, C., Lampropoulos, I. C., Dardiotis, E., Speletas, M. G., Ntavaroukas, P., Androutsopoulou, A., Kalala, F., Grigoriadis, N., & Papoutsopoulou, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010264 · Cited by 65
Ruiz-Pozo, V. A., Tamayo-Trujillo, R., Cadena-Ullauri, S., Frias-Toral, E., Guevara-Ramírez, P., Paz-Cruz, E., Chapela, S., Montalván, M., Morales-López, T., Simancas-Racines, D., et al. (2023) · Nutrients · doi:10.3390/nu15163585 · Cited by 63
Masuda, H., Mori, M., Uzawa, A., Uchida, T., Ohtani, R., Kobayashi, S., & Kuwabara, S. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.11.041 · Cited by 63
Angelopoulou, E., Stanitsa, E., Karpodini, C. C., Bougea, A. M., Kontaxopoulou, D., Fragkiadaki, S., Koros, C., Georgakopoulou, V., Fotakopoulos, G., Koutedakis, Y., et al. (2023) · Medicina · doi:10.3390/medicina59081454 · Cited by 63
Rocha, N. P., Reis, H. J., Berghe, P. V., & Cirillo, C. (2014) · NeuroImmunoModulation · doi:10.1159/000356531 · Cited by 63
Manocha, G. D., Floden, A. M., Puig, K. L., Nagamoto-Combs, K., Scherzer, C. R., & Combs, C. K. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0158-z · Cited by 60
Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson’s Disease
Rocha, N. P., Scalzo, P. L., Barbosa, I. G., de Souza, M. S., Morato, I. B., Vieira, É. L. M., Christo, P. P., Teixeira, A. L., & Reis, H. J. (2014) · Parkinson s Disease · doi:10.1155/2014/903796 · Cited by 63
How should we be using biomarkers in trials of disease modification in Parkinson’s disease?
Vijiaratnam, N., & Foltynie, T. (2023) · Brain · doi:10.1093/brain/awad265 · Cited by 59
Neuroinflammation and Autophagy in Parkinson’s Disease—Novel Perspectives
Minchev, D. S., Kazakova, M., & Sarafian, V. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314997 · Cited by 58
Proinflammatory Cytokines Are Elevated in Serum of Patients with Multiple System Atrophy
Kaufman, E., Hall, S., Surova, Y., Widner, H., Hansson, O., & Lindqvist, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062354 · Cited by 53
Self-citationInflammatory Bowel Disease and Neurodegenerative Diseases
Kim, J. S., Chen, M., Wang, H. E., Lu, C., Wang, Y., & Zhang, B. (2023) · Gut and Liver · doi:10.5009/gnl220523 · Cited by 57
Tau/α‐synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study
Delgado‐Alvarado, M., Gago, B., Gorostidi, A., Jiménez‐Urbieta, H., Dacosta‐Aguayo, R., Navalpotro‐Gómez, I., Ruiz‐Martínez, J., Bergareche, A., Martí‐Massó, J. F., Martínez‐Lage, P., et al. (2017) · Movement Disorders · doi:10.1002/mds.27001 · Cited by 50
Prevention of Oxidative Stress and Diseases by Antioxidant Supplementation
Martemucci, G., Portincasa, P., Centonze, V., Mariano, M., Khalil, M., & D‘Alessandro, A. G. (2022) · Medicinal Chemistry · doi:10.2174/1573406419666221130162512 · Cited by 54
Chen, D., Wei, X., Zou, J., Wang, R., Liu, X., Xu, X., Lu, J., Wang, Z., Tang, B., Wang, B. Z., et al. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00247 · Cited by 54
The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue
Lucas, K., Morris, G., Anderson, G., & Maes, M. H. J. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527314666150317224645 · Cited by 54
The complex role of inflammation and gliotransmitters in Parkinson's disease
Gopinath, A., Mackie, P. M., Phan, L. T., Tansey, M. G., & Khoshbouei, H. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105940 · Cited by 55
Fatigue in Parkinson's Disease
Kluger, B. M. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.05.007 · Cited by 54
Interleukin 6 and complement serum level study in Parkinson’s disease
Veselý, B., Dufek, M., Thon, V., Brozman, M., Királová, S., Halászová, T., Koriťáková, E., & Rektor, I. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1857-5 · Cited by 51
Inflammation and fatigue in early, untreated Parkinson's Disease
Herlofson, K., Heijnen, C. J., Lange, J., Alves, G. W., Tysnes, O., Friedman, J. H., & Fagundes, C. P. (2018) · Acta Neurologica Scandinavica · doi:10.1111/ane.12977 · Cited by 46
Baseline Plasma C-Reactive Protein Concentrations and Motor Prognosis in Parkinson Disease
Umemura, A., Oeda, T., Yamamoto, K., Tomita, S., Kohsaka, M., Park, K., Sugiyama, H., & Sawada, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136722 · Cited by 44
Marschallinger, J., Altendorfer, B., Rockenstein, E. M., Holztrattner, M., Garnweidner-Raith, J., Pillichshammer, N., Leister, I., Hutter‐Paier, B., Strempfl, K., Unger, M. S., et al. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00836-3 · Cited by 44
Immune-related biomarkers for Parkinson's disease
Abdi, I. Y., Ghanem, S. S., & El‐Agnaf, O. M. A. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105771 · Cited by 44
The molecular mechanism of aging and the role in neurodegenerative diseases
Zhao, J.-L., Han, Z.-J., Ding, L., Wang, P., He, X.-T., & Lin, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24751 · Cited by 33
Vaccination strategies for Parkinson disease: Induction of a swift attack or raising tolerance?
Romero‐Ramos, M., Chelpin, M. V. E., & Sánchez-Guajardo, V. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.28578 · Cited by 43
The Intersection of Parkinson’s Disease, Viral Infections, and COVID-19
Rosen, B., Kurtishi, A., Vazquez-Jimenez, G. R., & Møller, S. G. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02408-8 · Cited by 41
Hu, Y., Yu, S., Zuo, L.-J., Piao, Y., Cao, C.-J., Wang, F., Chen, Z., Du, Y., Lian, T., Liu, G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138997 · Cited by 41
Aktaş, B., Aslım, B., & Özdemir, D. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-65061-w · Cited by 40
Moon, S., Schmidt, M., Smirnova, I. V., Colgrove, Y., & Liu, W. (2017) · Medicines · doi:10.3390/medicines4020023 · Cited by 40
Microglia in Neurodegenerative Events—An Initiator or a Significant Other?
Harry, G. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115818 · Cited by 40
Is the Enzyme ACMSD a Novel Therapeutic Target in Parkinson’s Disease?
Rajamani, K. T., Li, P., Galvis, M. L. E., Labrie, V., Brundin, P., & Brundin, L. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-171240 · Cited by 39
Self-citationLangley, M. R., Ghaisas, S., Palanisamy, B. N., Ay, M., Jin, H., Anantharam, V., Kanthasamy, A., & Kanthasamy, A. G. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113716 · Cited by 39
Wang, H., Liu, Y., Zhao, J., Guo, X., Hu, M., & Chen, Y. (2021) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2021.106844 · Cited by 39
Cholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinson’s Disease
Iarkov, A., Mendoza, C., & Echeverría, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.665820 · Cited by 39
Peripheral inflammatory cytokines and motor symptoms in persons with Parkinson's disease
Diaz, K., Kohut, M. L., Russell, D. W., & Stegemöller, E. L. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100442 · Cited by 40
Systemic Inflammation in Lewy Body Diseases: A Systematic Review
King, E., & Thomas, A. J. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000211 · Cited by 39
Therapeutic modulation of JAK-STAT, mTOR, and PPAR-γ signaling in neurological dysfunctions
Kumar, S., Mehan, S., & Narula, A. S. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02272-6 · Cited by 38
Serum Inflammatory Markers and Progression of Nonmotor Symptoms in Early Parkinson's Disease
Kim, R., Kim, H., Shin, J. H., Lee, C. Y., Jeon, S. H., & Jeon, B. (2022) · Movement Disorders · doi:10.1002/mds.29056 · Cited by 37
Chiu, Y., Lin, C., Lin, C., Yang, P.-N., Lo, Y., Chen, Y.-C., Chen, C., Wu, Y., Yao, C., Chang, K., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032642 · Cited by 37
Parkinson's Disease and Its Management: Part 4: Treatment of Motor Complications.
DeMaagd, G. A., & Philip, A. (2015) · PubMed · Cited by 36
Metadata
- Authors
- Lindqvist, D., Kaufman, E., Brundin, L., Hall, S., Surova, Y., & Hansson, O.
- Affiliations
- Lund University (SE)
- Corresponding author
- Lindqvist, Daniel
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-10-17
- Volume
- 7
- Issue
- 10
- Pages
- e47387
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3474801
- OpenAlex
- W2107646604
- Cited by
- 236
- References
- 48
- Citations by year
- 2026: 14 · 2025: 19 · 2024: 22 · 2023: 19 · 2022: 27 · 2021: 21 · 2020: 17 · 2019: 16 · 2018: 16 · 2017: 13 · 2016: 15 · 2015: 15 · 2014: 16 · 2013: 6
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- Funders
- Lunds Universitet
- Vetenskapsrådet
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, non-motor symptoms, fatigue, depression, anxiety, sleep disorders, inflammatory cytokines, interleukin-6, soluble interleukin-2 receptor, TNF-α, C-reactive protein, neuroinflammation
- MeSH terms
- C-Reactive Protein, Female, Humans, Male, Middle Aged, Motor Activity, Parkinson Disease, Regression Analysis, Tumor Necrosis Factor-alpha, Receptors, Interleukin-2, Interleukin-6, Confounding Factors, Epidemiologic, Case-Control Studies, Cytokines, Inflammation Mediators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.